RSS   Newsletter   Contact   Advertise with us

Pfizer hikes U.S. prices for more than 100 drugs

Share on Twitter Share on LinkedIn
Staff writer ▼ | January 9, 2016
Pfizer on January 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20 percent, according to statistics compiled by Wolters Kluwer.
Pfizer
Pharma industry   New year, new prices from the pharmaceutical giant
Pfizer confirmed a 9.4 percent increase for heavily advertised pain drug Lyrica, which generated $2.3 billion in 2014 U.S. sales; a 12.9 percent increase for erectile dysfunction drug Viagra, which had 2014 U.S. sales of $1.1 billion; and a 5 percent increase for Ibrance, a novel breast cancer drug launched last year at a list price of $9,850 per month, or $118,200 per year.

Those price increases were compiled by a unit of Wolters Kluwer Health and published in a research note by UBS Securities. UBS said Pfizer increased prices by 20 percent for anticonvulsant Dilantin, hormone therapy Menest, angina drug Nitrostat, Tykosyn for irregular heartbeat, and antibiotic Tygacil.

The analyst report said U.S. prices were raised on a total of 105 Pfizer drugs. No price reductions were reported.


 

MORE INSIDE POST